MS patients may someday find relief in marijuana chewing gum

Patients can smoke it, eat it and soon, they may be able to chew it.

Cannabis-focused biotech company AXIM Biotechnologies AXIM, -92.56% last week said it launched clinical trials on humans for medical cannabis chewing gum as a treatment for multiple sclerosis. The gum, MedChew RX, contains 5 milligrams of cannabidiol — a non-psychoactive component of cannabis — and 5 milligrams of THC — a psychoactive cannabinoid.

Medical marijuana chewing gum “should allow for predictable and controlled release of the active ingredients,” George Anastassov, chief executive of AXIM, said in a statement. It should not be socially stigmatizing, should have a pleasant taste and consistency and no undesirable side effects, he added. “Chewing gum meets all these criteria.”

AXIM already has a cannabinoid chewing gum product, known as CanChew, on the market, however it does not contain THC and does not offer any medical claims.

The psychoactive...

Rate this article: 
Region: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.


URL: 
http://www.marketwatch.com/story/ms-patients-may-someday-find-relief-in-marijuana-chewing-gum-2015-08-17